Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
710 hedge funds and large institutions have $39.1B invested in Alexion Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 242 increasing their positions, 295 reducing their positions, and 102 closing their positions.
25% more capital invested
Capital invested by funds: $31.3B → $39.1B (+$7.78B)
10% more funds holding in top 10
Funds holding in top 10: 70 → 77 (+7)
6% less funds holding
Funds holding: 754 → 710 (-44)
18% less repeat investments, than reductions
Existing positions increased: 242 | Existing positions reduced: 295
34% less first-time investments, than exits
New positions opened: 67 | Existing positions closed: 102
73% less call options, than puts
Call options by funds: $108M | Put options by funds: $403M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$491M |
| 2 |
Millennium Management
New York
|
+$391M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$332M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$245M |
| 5 |
DKCM
Davidson Kempner Capital Management
New York
|
+$242M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$611M |
| 2 |
SC
Sculptor Capital
New York
|
-$247M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$222M |
| 4 |
PC
Paulson & Co
New York
|
-$214M |
| 5 |
Barclays
London,
United Kingdom
|
-$194M |
ALXN Hedge Fund Activity: Q2 2021 in Review
710 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2021, worth a combined $39.1B — up 25% from $31.3B a quarter earlier.
Sellers outnumbered buyers: 102 funds closed out of ALXN and 67 opened new positions — a net loss of 35 holders — while 295 trimmed existing stakes and 242 added.
The largest buyer was UBS O'Connor, adding an estimated $491M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $611M sold.
- 710 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2021, down from 754 in Q1 2021.
- Funds reported $39.1B of Alexion Pharmaceuticals stock for Q2 2021, up 25% quarter-over-quarter.
- 67 funds opened new Alexion Pharmaceuticals positions in Q2 2021 and 102 closed out, a net change of -35 holders.
- The largest Alexion Pharmaceuticals buyer in Q2 2021 was UBS O'Connor, an estimated $491M added.
- The largest Alexion Pharmaceuticals seller in Q2 2021 was Baker Bros. Advisors, an estimated $611M sold.
Based on aggregated 13F filings for Q2 2021.